Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies.
Biotechnique™ is a sterile injectable and clinical oncolytics company located in Madison, WI USA, dedicated to providing cytotoxic and high potency sterile injectable fill-finish services
Small Molecule Discovery (oncology)
Heat-Activated Liposomal Technology, Oncology
Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics.
Drug Development: Our portfolio of Tranlsational Platforms for Oncology and CVMD provide insight and understanding about a drug's efficacy, pharmacological profile and patient response profile, ...
CureMatch uses advanced algorithms, genomics, and data from prior patients to analyze millions of cancer treatment options.
Develops monoclonal microbials. Monoclonal microbials are orally-delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut.
Contract research services in pharmacokinetics, toxicology, oncology, metabolic diseases, wound healing, and animal model development.
Flatiron develops databases from electronic health records of over 265 community clinics and academic institutions at over 800 geographically diverse sites of care.
Oncology Drug Development
GenePath Dx provides molecular diagnostics to the medical, healthcare and allied communities. Their portfolio includes DNA and RNA based tests for Infectious Diseases, Oncology, ...
Plant-derived small molecules for oncology
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology ...
Talaporfin Sodium for solid tumors
Drugs for oncology & infectious diseases
Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Its mission is to change the treatment for chronic ...
Tumor Treating Fields
Oncology Venture will utilize the technology and acquire product rights or co-develop with drug owners where OV’s technology can predict efficacy.
Tumor-Targeting Small Molecules